SAN FRANCISCO, March 4, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the “PIPE”) for gross…Read More
“When I agreed to join Hansen Medical, I knew we faced a multitude of challenges that had to be promptly addressed. As we evaluated the capital needs and cost structure of the company, I needed a CFO who could be a balanced and trusted business partner. I needed someone to ensure my strategy was being implemented effectively, essentially an extension of me. Chris Lowe, my FLG partner, was immediately effective in guiding our financing strategy and implementing our cost reduction plans. The success of these programs allowed us to then pursue a strategic sale. Our achievements could not have been done without FLG’s support.”